Myotonometer Intra- and Inter Examiner Reliability on Spinal Muscular Atrophy

Medipol Health Group

Status: Invitation-only

Conditions: Muscle Tone Poor; Spinal Muscular Atrophy

Treatments: Diagnostic Test: MyotonPRO

Study type: Observational

Funder types: Other

Identifiers

NCT05521217

E-10840098-772.02-3771

Details and patient eligibility

About

The primary aim of the study was to measure the intra-rater and inter-rater reliability of MyotonPRO in measuring postural muscle tone and mechanical properties in individuals with spinal muscular atrophy (SMA). The secondary aim is to question the existence of a relationship between the functional levels of individuals with SMA and their muscle tone and biomechanical properties. It is assumed that the outputs to be obtained from this research will form the norm data for moyotonometer evaluation in children with SMA.

Full description

It seems to be important to examine peripheral changes in the pathogenesis of SMA. Although it shows that the target center in SMA is alpha motor neurons located in the anterior horn of the spinal cord, considering the interaction network of interneurons, cerebellum, neuromuscular junction, gamma-alpha motor neuron pool, descending and ascending pathways, and reflex arc, it has potential to be investigated in individuals with SMA. This suggests that it may have important consequences for peripheral mechanisms. It may be important to examine muscle mechanical properties to reveal any potential correlations between SMA types and disease progression. In addition, moyotonometer results can be a key evaluation method in examining treatment efficacy, diagnosis and disease course. However, in order for these activities to be observed with myotonometer, first of all, the reliability of its use in individuals with SMA should be questioned.

Enrollment: 30 estimated patients

Sex: All

Ages: 1 month to 4 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Between 0-4 years old
• Diagnosed with spinal muscular atrophy (SMA)
• Children who continue their medical treatment at home and are not in intensive care
• Children of families who agreed to participate in the study and approved the informed consent form.

Exclusion criteria

• Children of families who disagreed to participate in the study

Trial design

30 participants in 2 patient groups

Children with Spinal Muscular Atrophy

Description:

The patients were included if they were between 0 to 4 yeats, with a diagnosis of Spinal Muscular Atrophy.

Treatment:

Diagnostic Test: MyotonPRO

Healthy children

Description:

The healthy age-matched control group was included.

Treatment:

Diagnostic Test: MyotonPRO